Pfizer says COVID-19 vaccine safe, effective in younger children

Today Pfizer-BioNTech released results from the first phase 2/3 trial of its COVID-19 mRNA vaccine on children ages 5 to 11, and said the vaccine was both safe and produced neutralizing antibodies to the novel coronavirus.

The trail considered a two-dose regimen of 10 micrograms (µg) administered 21 days apart, a smaller dose than the 30 µg dose used for people 12 and older, Pfizer said in a press release. The study included 2,268 participants. The trial is also studying that dose in children ages 6 months to 11 years.

“Over the past nine months, hundreds of millions of people ages 12 and older from around the world have received our COVID-19 vaccine. We are eager to extend the protection afforded by the vaccine to this younger population, subject to regulatory authorization, especially as we track the spread of the Delta variant and the substantial threat it poses to children,” said Pfizer CEO Albert Bourla.

Pfizer said it would be submitting applications for use to regulatory bodies as soon as possible, and ideally would see vaccination begin in this age group by the beginning of winter.



read the full story